Publication: RING1B contributes to Ewing sarcoma development by repressing the Na(V)1.6 sodium channel and the NF-kappa B pathway, independently of the fusion oncoprotein
dc.contributor.author | Hernandez-Munoz, Inmaculada | |
dc.contributor.author | Figuerola, Elisabeth | |
dc.contributor.author | Sanchez-Molina, Sara | |
dc.contributor.author | Rodriguez, Eva | |
dc.contributor.author | Isabel Fernandez-Marino, Ana | |
dc.contributor.author | Pardo-Pastor, Carlos | |
dc.contributor.author | Isabel Bahamonde, Maria | |
dc.contributor.author | Fernandez-Fernandez, Jose M. | |
dc.contributor.author | Garcia-Dominguez, Daniel J. | |
dc.contributor.author | Hontecillas-Prieto, Lourdes | |
dc.contributor.author | Lavarino, Cinzia | |
dc.contributor.author | Carcaboso, Angel M. | |
dc.contributor.author | de Torres, Carmen | |
dc.contributor.author | Tirado, Oscar M. | |
dc.contributor.author | de Alava, Enrique | |
dc.contributor.author | Mora, Jaume | |
dc.contributor.authoraffiliation | [Hernandez-Munoz, Inmaculada] Fdn Inst Hosp del Mar Invest Med FIMIM, E-08003 Barcelona, Spain | |
dc.contributor.authoraffiliation | [Figuerola, Elisabeth] Hosp St Joan de Deu, Dept Pediat Hematol & Oncol, Dev Tumor Biol Lab, Barcelona 08950, Spain | |
dc.contributor.authoraffiliation | [Sanchez-Molina, Sara] Hosp St Joan de Deu, Dept Pediat Hematol & Oncol, Dev Tumor Biol Lab, Barcelona 08950, Spain | |
dc.contributor.authoraffiliation | [Rodriguez, Eva] Hosp St Joan de Deu, Dept Pediat Hematol & Oncol, Dev Tumor Biol Lab, Barcelona 08950, Spain | |
dc.contributor.authoraffiliation | [Lavarino, Cinzia] Hosp St Joan de Deu, Dept Pediat Hematol & Oncol, Dev Tumor Biol Lab, Barcelona 08950, Spain | |
dc.contributor.authoraffiliation | [Carcaboso, Angel M.] Hosp St Joan de Deu, Dept Pediat Hematol & Oncol, Dev Tumor Biol Lab, Barcelona 08950, Spain | |
dc.contributor.authoraffiliation | [de Torres, Carmen] Hosp St Joan de Deu, Dept Pediat Hematol & Oncol, Dev Tumor Biol Lab, Barcelona 08950, Spain | |
dc.contributor.authoraffiliation | [Mora, Jaume] Hosp St Joan de Deu, Dept Pediat Hematol & Oncol, Dev Tumor Biol Lab, Barcelona 08950, Spain | |
dc.contributor.authoraffiliation | [Isabel Fernandez-Marino, Ana] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Lab Fisiol Mol, E-08003 Barcelona, Spain | |
dc.contributor.authoraffiliation | [Pardo-Pastor, Carlos] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Lab Fisiol Mol, E-08003 Barcelona, Spain | |
dc.contributor.authoraffiliation | [Isabel Bahamonde, Maria] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Lab Fisiol Mol, E-08003 Barcelona, Spain | |
dc.contributor.authoraffiliation | [Fernandez-Fernandez, Jose M.] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Lab Fisiol Mol, E-08003 Barcelona, Spain | |
dc.contributor.authoraffiliation | [Garcia-Dominguez, Daniel J.] Univ Seville, Hosp Univ Virgen del Rocio, CSIC, Inst Biomed Sevilla IBiS,Dept Pediat Hematol & On, E-41013 Seville, Spain | |
dc.contributor.authoraffiliation | [Hontecillas-Prieto, Lourdes] Univ Seville, Hosp Univ Virgen del Rocio, CSIC, Inst Biomed Sevilla IBiS,Dept Pediat Hematol & On, E-41013 Seville, Spain | |
dc.contributor.authoraffiliation | [de Alava, Enrique] Univ Seville, Hosp Univ Virgen del Rocio, CSIC, Inst Biomed Sevilla IBiS,Dept Pediat Hematol & On, E-41013 Seville, Spain | |
dc.contributor.authoraffiliation | [Tirado, Oscar M.] Inst Invest Biomed Bellvitge IDIBELL, Lab Oncol Mol, Sarcoma Res Grp, Barcelona 08908, Spain | |
dc.contributor.authoraffiliation | [Isabel Fernandez-Marino, Ana] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurosci & Biomol Chem, Madison, WI 53705 USA | |
dc.contributor.funder | Xarxa de Bancs de Tumors de Catalunya | |
dc.contributor.funder | Pla Director d'Oncologia de Catalunya | |
dc.contributor.funder | ISCIII-FEDER | |
dc.contributor.funder | Ministerio de Economia y Competitividad (MEC) | |
dc.contributor.funder | FEDER Funds | |
dc.contributor.funder | Asociacion Espanola Contra el Cancer (AECC) | |
dc.contributor.funder | AECC | |
dc.contributor.funder | MEC-FEDER | |
dc.contributor.funder | European FP7 Projects EuroSARC (FP7HEALTH-two-stage) | |
dc.contributor.funder | Euroewing | |
dc.contributor.funder | Fundacion Memoria de DM Solorzano Barruso | |
dc.contributor.funder | Fundacion Cris contra el Cancer | |
dc.contributor.funder | Pablo Ugarte Foundation | |
dc.contributor.funder | Fundacion M. Garcia Estrada | |
dc.contributor.funder | European FP7 projects (FP7) under a Marie Curie International Reintegration Grant | |
dc.date.accessioned | 2023-02-12T02:23:54Z | |
dc.date.available | 2023-02-12T02:23:54Z | |
dc.date.issued | 2016-07-19 | |
dc.description.abstract | Ewing sarcoma (ES) is an aggressive tumor defined by EWSR1 gene fusions that behave as an oncogene. Here we demonstrate that RING1B is highly expressed in primary ES tumors, and its expression is independent of the fusion oncogene. RING1B-depleted ES cells display an expression profile enriched in genes functionally involved in hematological development but RING1B depletion does not induce cellular differentiation. In ES cells, RING1B directly binds the SCN8A sodium channel promoter and its depletion results in enhanced Nav1.6 expression and function. The signaling pathway most significantly modulated by RING1B is NF-kappa B. RING1B depletion results in enhanced p105/p50 expression, which sensitizes ES cells to apoptosis by FGFR/ SHP2/STAT3 blockade. Reduced Na(V)1.6 function protects ES cells from apoptotic cell death by maintaining low NF-kappa B levels. Our findings identify RING1B as a trait of the cell-of-origin and provide a potential targetable vulnerability. | |
dc.identifier.doi | 10.18632/oncotarget.10092 | |
dc.identifier.essn | 1949-2553 | |
dc.identifier.unpaywallURL | http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=10092&path%5B%5D=31735 | |
dc.identifier.uri | http://hdl.handle.net/10668/19432 | |
dc.identifier.wosID | 385402300111 | |
dc.issue.number | 29 | |
dc.journal.title | Oncotarget | |
dc.journal.titleabbreviation | Oncotarget | |
dc.language.iso | en | |
dc.organization | Instituto de Biomedicina de Sevilla-IBIS | |
dc.organization | Hospital Universitario Virgen del Rocío | |
dc.page.number | 46283-46300 | |
dc.publisher | Impact journals llc | |
dc.rights | Attribution 4.0 International | |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | RING1B | |
dc.subject | Ewing sarcoma | |
dc.subject | voltage-gated sodium channel | |
dc.subject | NF-kappa B | |
dc.subject | FGFR/SHP2/STAT3 | |
dc.subject | Fibroblast-growth-factor | |
dc.subject | Marrow stromal cells | |
dc.subject | In-vivo | |
dc.subject | Neuroectodermal tumors | |
dc.subject | Neural differentiation | |
dc.subject | Tyrosine-phosphatase | |
dc.subject | Genomic landscape | |
dc.subject | Histone h2a | |
dc.subject | Stem-cells | |
dc.subject | Family | |
dc.title | RING1B contributes to Ewing sarcoma development by repressing the Na(V)1.6 sodium channel and the NF-kappa B pathway, independently of the fusion oncoprotein | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 7 | |
dc.wostype | Article | |
dspace.entity.type | Publication |